Clinical and serological study of human alveolar echinococcosis in Slovakia in relation to the outcome of chemotherapy

SummaryAlveolar echinococcosis (AE), caused by proliferating metacestodes of the parasitic fox tapeworm Echinococcus multilocularis, is a life-threatening disease in humans. In this study we report four human cases of AE in Slovak Republic with regard to various clinical manifestations and susceptibility to chemotherapy with albendazole or mebendazole. Patients were monitored serologically by ELISA test and Western Blots within 2–5 years after initiation of chemotherapy/surgery. Using computerized tomography (CT) we compared morphological changes of the parasitic lesions in the liver during the course of treatment.The parasitic lesions in the CT were manifested as nodular hyperplasia with hyper or hypodense zones and calcified foci within the lesion. In other cases the lesion was visualised as a hypodense poorly-delineated septated focus without calcifications. In the last case, the diagnosis of AE was confirmed only at surgery. Calcified foci found inside the main parasitic lesions were the only abnormality that was detected in two cases and were absent in other two cases. The levels of specific anti-parasitic antibodies followed the pathomorphological changes in the livers. Total IgG levels to Em2+ and EmP antigen declined gradually during the follow-up (1–5 years) and disappeared only in the patient receiving radical surgery (cured). In comparison with total IgG, concentration of the IgG4 antibody subclass seemed to correlate more adequately with the outcome of therapy as their levels decreased in improved/stabilised patients, but were elevated in “aggravated” patients. We showed that, in patients with AE in Slovakia, radical surgery of parasitic foci proved to be the most successful treatment and, in inoperable cases, albendazole and mebendazole were differently effective. Moreover. IgG4 levels rather than total IgG to protoscoleces antigens proved to be more sensitive serological marker of the progress of therapy.

[1]  Philip Craig.  Echinococcus multilocularis , 2003, Current opinion in infectious diseases.

[2]  A D Dayan,et al.  Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. , 2003, Acta tropica.

[3]  H. Auer,et al.  European Echinococcosis Registry: Human Alveolar Echinococcosis, Europe, 1982–2000 , 2003, Emerging infectious diseases.

[4]  K. Nuessle,et al.  Alveolar Liver Echinococcosis: A Comparative Study of Three Imaging Techniques , 2001, Infection.

[5]  Patrick Giraudoux,et al.  Alveolar echinococcosis : characteristics of a possible emergence and new perspectives in epidemiosurveillance , 2001 .

[6]  F. Meslin,et al.  Prevention of echinococcosis in humans and safety precautions. , 2001 .

[7]  F. Meslin,et al.  WHO/OIE manual on echinococcosis in humans and animals: a public health problem of global concern. , 2001 .

[8]  W. Kratzer,et al.  Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. , 2000, The Journal of antimicrobial chemotherapy.

[9]  G. Kokwaro,et al.  Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. , 2000, British journal of clinical pharmacology.

[10]  H. Schirrmeister,et al.  Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  P. Deplazes,et al.  Alveolar echinococcosis in humans: the current situation in Central Europe and the need for countermeasures. , 1999, Parasitology today.

[12]  J. Uchino,et al.  Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery , 1997, Hepatology.

[13]  R. Jaussi,et al.  Alveoläre Echinokokkose der Leber mit lymphogener, pulmonaler und zerebraler Metastasierung , 1996 .

[14]  H. Wen,et al.  Analysis of immunoglobulin G subclass in the serum antibody responses of alveolar echinococcosis patients after surgical treatment and chemotherapy as an aid to assessing the outcome. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  R. Riganò,et al.  Immunological markers indicating the effectiveness of pharmacological treatment in human hydatid disease , 1995, Clinical and experimental immunology.

[16]  R. Lucius,et al.  Echinococcus multilocularis in germany: increased awareness or spreading of a parasite? , 1995, Parasitology today.

[17]  J. Brook,et al.  Rhabdomyolysis complicating acute Epstein-Barr virus infection , 1995, Infection.

[18]  J. Wilson,et al.  Em18, a new serodiagnostic marker for differentiation of active and inactive cases of alveolar hydatid disease. , 1995, The American journal of tropical medicine and hygiene.

[19]  H. Wen,et al.  Immunoglobulin G subclass responses in human cystic and alveolar echinococcosis. , 1994, The American journal of tropical medicine and hygiene.

[20]  A. Freiburghaus,et al.  Effect of chemotherapy on the larval mass and the long‐term course of alveolar echinococcosis , 1994, Hepatology.

[21]  P. Craig,et al.  Immune status during albendazole therapy for hydatidosis. , 1992, Annals of tropical medicine and parasitology.

[22]  D. Heiner,et al.  Immunoglobulin E and G4 antibodies in cysticercosis , 1990, Journal of clinical microbiology.

[23]  R. Ammann,et al.  Em2-ELISA for the follow-up of alveolar echinococcosis after complete surgical resection of liver lesions. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[24]  D. Didier,et al.  Hepatic alveolar echinococcosis: correlative US and CT study. , 1985, Radiology.

[25]  R. Molimard,et al.  Treatment of echinococcosis. , 1978, British medical journal.

[26]  Bourgeon,et al.  [Liver and the biliary tract]. , 1955, Afrique francaise chirurgicale.